Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA drug recalls in 2012

Every FDA drug recall initiated in 2012, newest first, with its risk class, status and the reason the FDA recorded. Use the cause and risk filters to narrow the year down.

534 recalls, newest first.

Total recalls
534
Class I (high risk)
49
Currently ongoing
2
Most recent
Dec 28, 2012
Class II · Moderate risk

Hillyard

Microbial Contamination of Non-Sterile Products: The product may be contaminated with bacteria.

Terminated Microbial contamination Hillyard GMP NDC 76402-403-03 D-140-2013
Class III · Low risk

Lac-Hydrin

Crystallization: Recall is due to a non-characteristic gritty/sandy texture to the product which is likely due to some crystallization of the product.

Terminated Failed specification Ranbaxy Inc. NDC 10631-099-28 D-163-2013
Class III · Low risk

Lac-Hydrin

Crystallization: Recall is due to a non-characteristic gritty/sandy texture to the product which is likely due to some crystallization of the product.

Terminated Failed specification Ranbaxy Inc. NDC 10631-098-14 D-162-2013
Class I · High risk

Super Power capsules

Marketed Without An Approved NDA/ANDA: This dietary supplement has been found to contain sildenafil, an FDA approved drug for the treatment of male erectile dysfunction making this an unapproved new drug.

Terminated Chemical / undeclared D& S Herbals, LLC D-323-2013
Class II · Moderate risk

12-Hour Sinus

Microbial Contamination of a Non-Sterile Products: 12-Hour Sinus Nasal Spray under various labeling are being recalled due to microbial contamination identified during testing.

Terminated Microbial contamination Lee Pharmaceuticals, Inc NDC 68016-0307-03 D-161-2013
Class III · Low risk

Femtrace 0.45 mg

Failed Impurity/Degradation Specifications due to moisture ingress in individual bottles

Terminated Impurity / degradation Warner Chilcott Company LLC D-142-2013
Class III · Low risk

Femtrace 0.9 mg

Failed Impurity/Degradation Specifications due to moisture ingress in individual bottles

Terminated Impurity / degradation Warner Chilcott Company LLC D-141-12013
Class I · High risk

SLIMDIA Revolution capsules

Marketed Without an Approved NDA/ANDA: All lots of the dietary supplement Slimdia Revolution are being recalled because they contain sibutramine, a previously approved FDA drug removed from the U.S. marketplace for safety reasons, making it an unapproved new drug.

Terminated Chemical / undeclared P & J Trading Co D-165-2013
Class II · Moderate risk

Taztia XT

Failed Dissolution Specification: Out of a specification result occurred during the 3-month stability testing. Dissolution result at the 4-hour time point was 41% (specification: 20-40%).

Terminated Dissolution failure Watson Pharmaceuticals NDC 62037-700-90 D-145-2013
Class I · High risk

CASANOVA Capsules

Marketed Without an Approved NDA/ANDA: product may contain undeclared sildenafil, tadalafil and analogues of these FDA approved active ingredients, making them unapproved drugs

Terminated Chemical / undeclared Performance Plus Marketing, Inc. D-338-2013
Class I · High risk

Mojo nights SUPREME Capsules

Marketed Without an Approved NDA/ANDA: product may contain undeclared sildenafil, tadalafil and analogues of these FDA approved active ingredients, making them unapproved drugs

Terminated Chemical / undeclared Performance Plus Marketing, Inc. D-337-2013
Class I · High risk

Mojo nights Capsules

Marketed Without an Approved NDA/ANDA: product may contain undeclared sildenafil, tadalafil and analogues of these FDA approved active ingredients, making them unapproved drugs

Terminated Chemical / undeclared Performance Plus Marketing, Inc. D-336-2013
Class I · High risk

BLUE Diamond PLATINUM Capsules

Marketed Without an Approved NDA/ANDA: product may contain undeclared sildenafil, tadalafil and analogues of these FDA approved active ingredients, making them unapproved drugs

Terminated Chemical / undeclared Performance Plus Marketing, Inc. D-335-2013
Class I · High risk

BLUE Diamond Pill

Marketed Without an Approved NDA/ANDA: product may contain undeclared sildenafil, tadalafil and analogues of these FDA approved active ingredients, making them unapproved drugs

Terminated Chemical / undeclared Performance Plus Marketing, Inc. D-334-2013
Class I · High risk

libigrow XXXTREME Capsules

Marketed Without an Approved NDA/ANDA: product may contain undeclared sildenafil, tadalafil and analogues of these FDA approved active ingredients, making them unapproved drugs

Terminated Chemical / undeclared Performance Plus Marketing, Inc. D-333-2013
Class I · High risk

libigrow capsules

Marketed Without an Approved NDA/ANDA: product may contain undeclared sildenafil, tadalafil and analogues of these FDA approved active ingredients, making them unapproved drugs

Terminated Chemical / undeclared Performance Plus Marketing, Inc. D-332-2013
Class II · Moderate risk

Prednisone tablets

Presence of Foreign Substance(s); Perrigo has been notified of a recall by the manufacturer of this product, West-Ward Pharmaceuticals. This is a sub-recall due to tablets contaminated with trace amounts of food-grade lubricant, as well as stainless steel inclusions

Terminated Particulate / foreign matter L. Perrigo Co. D-125-2013
Class II · Moderate risk

Temodar (temozolomide)

Failed Impurities/Degradation Specifications: The recall is being initiated due to an out-of-specification result in the degradation product testing detected during stability monitoring.

Terminated Impurity / degradation Schering-Plough Products, LLC D-139-2013
Class III · Low risk

Perindopril Erbumine Tablets

Impurities/Degradation Products: Out of Specification results found for impurity B, identified as the drug's metabolite.

Terminated Impurity / degradation Boehringer Ingelheim Roxane Inc NDC 0054-0112-25 D-126-2013

Recalls by year